83 related articles for article (PubMed ID: 2085697)
1. Ex vivo spermine dialdehyde treatment prevents lethal GVHD in a murine bone marrow transplantation model.
Wang E; Conant JM; Li D; Visconti V; Chourmouzis E; Lau C
Bone Marrow Transplant; 1990 Oct; 6(4):235-42. PubMed ID: 2085697
[TBL] [Abstract][Full Text] [Related]
2. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
3. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment.
Kohn FR; Sladek NE
Immunopharmacol Immunotoxicol; 1988; 10(3):387-98. PubMed ID: 3058776
[TBL] [Abstract][Full Text] [Related]
5. Spermine dialdehyde, a novel ex vivo purging agent for both allogenic and autologous bone marrow transplantations.
Lau C; Wang E; Ishaque A; Jones K; Wong B; Kimsto L; Conant J
Int J Immunopharmacol; 1992 Aug; 14(6):1081-91. PubMed ID: 1428363
[TBL] [Abstract][Full Text] [Related]
6. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
7. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
Palathumpat V; Holm B; Dejbakhsh-Jones S; Strober S
J Immunol; 1992 May; 148(10):3319-26. PubMed ID: 1578152
[TBL] [Abstract][Full Text] [Related]
8. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
[TBL] [Abstract][Full Text] [Related]
9. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cyclosporine-induced syngeneic graft-versus-host disease in bone marrow transplantation by UV-B irradiated bone marrow cells.
Ohajekwe OA; James T; Hardy MA; Oluwole SF
Bone Marrow Transplant; 1995 Apr; 15(4):627-32. PubMed ID: 7655391
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice.
Brok HP; Vossen JM; Heidt PJ
Bone Marrow Transplant; 1997 Mar; 19(6):601-6. PubMed ID: 9085739
[TBL] [Abstract][Full Text] [Related]
12. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
13. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
14. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
Georgantas RW; Bohana-Kashtan O; Civin CI
Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
[TBL] [Abstract][Full Text] [Related]
16. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression by succinylacetone. II. Prevention of graft-vs-host disease.
Hess RA; Tschudy DP; Blaese RM
J Immunol; 1987 Nov; 139(9):2845-9. PubMed ID: 2889780
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
19. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
20. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
